WuXi XDC Cayman Inc. (2268.HK)
HKSE · HKD · Healthcare · Diagnostics & Research
HK$69.25 (-1.70%) as of
Key statistics
- Market cap
- 87.70B
- P/E (TTM)
- 54.10
- Forward P/E
- 27.13
- EPS (TTM)
- 1.280
- Dividend yield
- 0.00%
- 52-week range
- 43.500 – 85.600
- Beta
- -0.87
- Revenue (TTM)
- 6.94B
- Profit margin
- 22.38%
- Analyst target
- HK$93.38
- Volume
- 5.36M
About WuXi XDC Cayman Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Wuxi, China
- Employees
- 3,628
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.